China Time

Topic

Speaker

Affiliation

15:45-15:55

Remarks and overview on Bayer R&D

Michael Brands

Head of Drug Discovery Sciences, Bayer

15:55-16:15

New Modalities research at Bayer and case studies – Targeted Protein degradation

Anja Giese

VP, Head of Novel Modalities I, Drug Discovery Sciences, Bayer

Revisiting Old Targets with New Drug Discovery Modalities

Philipp Cromm

Head of Laboratory, Drug Discovery Sciences, Bayer Science Fellow

16:15-16:25

Bayer’s targeted radiotherapy platform and its potential to unlock a broad opportunity space in cancer therapy

Urs Hagemann

Head of Targeted Radiopharmaceuticals Oncology, Bayer

Jenny Karlsson

Head of Radioassay Development and Screening, Bayer

16:25-16:55

Radiopharmaceuticals and Radiotherapy-Activated Prodrugs

Zhibo Liu

Associate Professor, Peking University

16:55-17:25

Migrasome, from biogenesis to therapeutic potential

Li Yu

Professor, Tsinghua University

17:25-17:30

Break

17:30-18:00

Identify cell-free noncoding RNA as biomarker and drug target

Zhi Lu

Associate Professor, Tsinghua University

18:00-18:30

Molecular Glue for Targeted Cancer Therapy

Xiangbing Qi

Associate Professor, National Institute of Biological Sciences

18:30-19:00

Molecular Glue Discovery: Serendipity or Inevitability?

Ting Han

Assistant Professor, National Institute of Biological Sciences